Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1024789

registered interest
date	13/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer: Staffordshire
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) increase early diagnosis rates for ovarian cancer and (b) increase access to treatment for ovarian cancer in specialist centres in Staffordshire.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	202081
answer	answer is ministerial correction date of answer 18/12/2018 answer text <p>Public Health England (PHE) has run a number of ‘Be Clear on Cancer’ campaigns to help improve early detection of cancer including ovarian cancer. In 2014 PHE ran a pilot regional ovarian cancer campaign in the North West of England. In 2017, PHE ran a pilot campaign in the East and West Midlands which focussed on a range of abdominal symptoms, such as diarrhoea, bloating and discomfort that can be indicative of a number of cancers, including ovarian cancer. NHS England has invested over £200 million between 2017 and 2019, supporting Cancer Alliances to accelerate diagnosis and enhance quality of life.</p><p> </p><p>Staffordshire clinical commissioning groups commission diagnostic services for ovarian cancer fully in line with National Institute for Health and Care Excellence guidelines across the whole sustainability and transformation partnership.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/12/2018 17:04:54 answering member 4067 label Biography information for Steve Brine
tabling member	1436 label Biography information for Paul Farrelly

1022956

registered interest
date	10/12/2018
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	Children: Social Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Education, what recent assessment he has made of the correlation between deprivation and demand for children’s services.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	200581
answer	answer is ministerial correction date of answer 13/12/2018 answer text <p>Demand for children’s services is associated with a number of factors, including deprivation. The most deprived local authorities (LAs) have more looked after children (per 10,000 17 year olds), and these rates have grown faster than the least deprived LAs.</p><p>In preparation for the Spending Review, to help ensure decisions are based on the best available evidence, the government is working with the sector to develop a sharper and more granular picture of demand for children’s services.</p><p>We are also working with Ministry of Housing, Communities and Local Government as part of the Government’s Fair Funding Review of relative needs and resources, where new, up-to-date formulas are being developed to ensure funding distribution to councils is based on the best available evidence.</p><p>We welcome the contributions from the sector in this area, including Newton Europe’s Making Sense (2018) report and the Association of Directors of Children’s Services' continuing research reports, Safeguarding Pressures (2018).</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/12/2018 14:41:48 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1436 label Biography information for Paul Farrelly

1020404

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA), and with reference to the transition period set out in the Agreement on the Withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union, if the MHRA will be recognised as an EU competent authority under the EU (a) Medical Devices Directive, (b) in-vitro diagnostic medical devices, and (c) Medical Devices Regulation during the period covered by the Agreement.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	199325
answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p> </p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p> </p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.</p><p> </p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 199327 question first answered 10/12/2018 14:12:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1436 label Biography information for Paul Farrelly

1020405

registered interest
date	05/12/2018
answering body	Department for Exiting the European Union
answering dept id	203
answering dept short name	Exiting the European Union
answering dept sort name	Exiting the European Union
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Exiting the European Union, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA) and with reference to the transition period set out in the Agreement on the Withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union, if the MHRA will be recognised as an EU competent authority under EU Regulations (a) Medical Devices Directive, (b) in-vitro diagnostic medical devices, and (c) Medical Devices Regulation during that period.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	199326
answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as an EU competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p><strong></strong><br><br></p><p> </p> answering member constituency Daventry answering member printed Chris Heaton-Harris question first answered 10/12/2018 15:48:34 answering member 3977 label Biography information for Chris Heaton-Harris
tabling member	1436 label Biography information for Paul Farrelly

1020408

registered interest
date	05/12/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: UK Notified Bodies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 03 December 2018 to Question 196736 on Medicines and Healthcare Products Regulatory Agency (MHRA), whether the Department's response refers to (a) UK notified bodies licensed by the MHRA and (b) UK notified bodies that have also secured notified body status in other EU states.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	199327
answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p> </p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p> </p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.</p><p> </p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 199325 question first answered 10/12/2018 14:12:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1436 label Biography information for Paul Farrelly